SCHEMBL3573592

SCHEMBL3573592

O=C1CCN(C2COC(=O)N2c2ccccc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.38
QPCT Q16769 1/20 0.34
RAB9A P51151 2/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
HSD11B1 P28845 1/20 0.33
POLB P06746 1/20 0.33
ALOX5 P09917 2/20 0.33
G6PD P11413 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7814733 0.88 ALDH1A1 (0.41) NOTUMQPCTRAB9AGAAMAPT
SCHEMBL7823338 0.88 NOTUM (0.40) NOTUMQPCTRAB9AGAAMAPT
SCHEMBL1843567 0.86 ALDH1A1 (0.43) NOTUMQPCTRAB9AGAAMAPT
SCHEMBL3260136 0.84 SIGMAR1 (0.42) NOTUMQPCTSMN1; SMN2KMT2AALOX5
SCHEMBL3575078 0.81 NOTUM (0.35) NOTUMQPCTRAB9AGAAMAPT
SCHEMBL3578214 0.80 MAPK1 (0.40) NOTUMQPCTRAB9AGAAMAPT
SCHEMBL2724582 0.76 ALDH1A1 (0.38) NOTUMMAPTSMN1; SMN2KMT2AALDH1A1
SCHEMBL3586944 0.76 ALDH1A1 (0.33) NOTUMQPCTGAAHSD11B1ALDH1A1
SCHEMBL3572019 0.76 IDH1 (0.32) NOTUMQPCTHSD11B1IDH1
SCHEMBL3578652 0.76 QPCT (0.32) NOTUMQPCTHSD11B1IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP claimed
EP-1565461-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Patel, Mahesh V. (IN) 2005-08-24 EP claimed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US claimed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO claimed
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED 2004-04-01 US claimed
WO-2004007489-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WOCKHARDT LIMITED (IN) 2004-01-22 WO claimed
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED 2010-06-10 US disclosed
US-7687627-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2010-03-30 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY GMPS, MPO, ARG1 NOTUM 2823/4885QPCT 470/4885RAB9A 911/4885
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy GMPS, MPO, ARG1 NOTUM 2823/4885QPCT 470/4885RAB9A 911/4885
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites POLRMT, RNASEL, RNASE1 NOTUM 4187/4885QPCT 719/4885RAB9A 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.